MedTrace Logo

EpigenOMic Determinants of the Neuroendocrine Phenotype As Biomarkers for Neuroendocrine Neoplasms

NCT06785597 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2025-01-21

No results posted yet for this study

Summary

For GEP mixed neuroendocrine (NE) non-neuroendocrine neoplasms (MiNENs) a key issue affecting prognosis is sometimes the difficulty in obtaining a timely diagnosis, as the NE component is often localized in deeper anatomical locations and/or becomes prevalent over time. The tissue material of biopsies may be not enough to define the NE component when this is particularly small and this could impact on therapeutic decision. Furthermore GEP NENs need to be characterized for potentially druggable biomarkers and liquid biopsy has clear advantage to the solid one to this aim. Here, we will exploit epigenetic differences characterizing NE tumors to build a DNA methylation-based liquid biopsy assay able to detect circulating tumor DNA of NE derivation, to enable the non-invasive diagnosis and monitoring of GEP-MiNENs.

Conditions

  • Mixed Neuroendocrine-Non Neuroendocrine Neoplasm
  • Neuroendocrine Neoplasm

Sponsors & Collaborators

  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo

    collaborator OTHER

  • European Institute of Oncology

    lead OTHER

Principal Investigators

  • Nicola Fazio, MD · European Institute of Oncology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-21
Primary Completion
2026-10-21
Completion
2026-10-21

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06785597 on ClinicalTrials.gov